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translation methodology included two forward transla-
tions by native speakers in each language, a reconciled
version of the two forwards by a third translator, back-
translation of the reconciled version by a native English
speaker ﬂuent in the target language, and three indepen-
dent reviews by native speaking experts. Retrospective
debrieﬁng interviews were conducted in which 113
patients (20 in Portugal, 20 in Japan, 19 in Brazil, 34 in
Israel, and 20 in Korea) diagnosed with multiple sclero-
sis were asked to read and answer the questionnaire in
Portuguese, Japanese, Hebrew, Russian, or Korean and
then give their opinion on any problems with the trans-
lation or the content of the questionnaire. Statistical
analyses (descriptive statistics and reliability analyses)
were performed on the quantitative data, and the partic-
ipant comments were reviewed. RESULTS: Age range
was 19 to 64 years; there were 75 women and 38 men.
The FAMS performed very well in all target languages.
Cronbach’s alpha coefﬁcients for total FAMS were high
(range = 0.93–0.96), indicating overall scale homogene-
ity comparable to the original English version. Based
upon statistical analyses and comments from patients, no
revisions were necessary for the Portuguese, Japanese,
Russian, and Korean translations. However, two revi-
sions were made to the Hebrew version as a result of data
collected during testing. CONCLUSIONS: Participants
were comfortable with the questionnaire and felt that the
questions addressed issues important to multiple sclero-
sis. The ﬁnal versions of the Portuguese, Japanese,
Hebrew, Russian, and Korean FAMS are linguistically
acceptable and show good psychometric performance,
and are now ready for inclusion in clinical trials and other
research studies to evaluate the quality of life of patients
with multiple sclerosis.
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OBJECTIVE: The complexity of peripheral diabetic 
neuropathy (PDN) and the highly variable effects of indi-
vidual drugs mean that clinicians continue to seek alter-
natives for their patients. The objective of this study was
to evaluate and describe the use of topiramate for PDN
in Canadian clinical practice. METHODS: Retrospective
review of 100 patient charts using physician interview.
Physicians were asked to include the 4 most recent
patients that met the following criteria: 1) diagnosis of
PDN; 2) topiramate started ≥6 months prior to review
date to allow an adequate trial time for drug therapy; 3)
no concomitant gabapentin use. RESULTS: Patient char-
acteristics: 8% Type 1 diabetes, 92% Type 2; mean age
55.4 years; 45% male; 85% Caucasian; 61% with
medical conditions other than diabetes /PDN requiring
drug therapy. Pain distribution: foot/toe 91%, calf 29%,
ﬁnger/hand 28%, thigh 19%. Pain quality: burning 55%,
tingling 47%, pins and needles 30%, aching 23%, sharp
19%, cramping 17%, jabbing 17%, shooting 17%. Top-
iramate therapy: mean duration 14.4 months; mean total
daily dose 136mg. 98% were current users. Patients had
PDN for 21.5 months on average prior to starting topi-
ramate therapy. Topiramate was used as monotherapy in
79%. In 59% topiramate was the ﬁrst-line drug. 24%
experienced topiramate-related adverse effects (AEs);
most common: dizziness 29%, somnolence 21%, nausea
17%, and numbness 13%. Actions taken for AEs: none
(71%), dose reduction (17%), slower titration (13%),
treatment with another drug (4%). According to physi-
cian assessment, 64% (95%CI 46, 82) were “very much
improved” or “much improved” for pain, 49% (95%CI
30, 68) for physical activity, and 51% (95%CI 33, 70)
for sleep. CONCLUSIONS: Under conditions of routine
clinical care, topiramate was effective in relieving pain
and improving physical activity and sleep in patients with
PDN. Most patients tolerated the drug long-term with no
discontinuation of therapy resulting from AEs.
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OBJECTIVE: Neuropathic pain is difﬁcult to manage and
pharmacotherapy is often unsatisfactory. Patients often
will have tried a large number of drugs in an effort to ﬁnd
relief. This study evaluated the effectiveness and safety of
topiramate in patients with peripheral diabetic neuropa-
thy (PDN) who have previously tried other anticonvul-
sants. METHODS: Retrospective review of 100 patient
charts using physician interview. Physicians were asked to
include the 4 most recent patients that met the following
criteria: 1) diagnosis of PDN; 2) topiramate started ≥6
months prior to review date to allow an adequate trial
time for drug therapy; 3) no concomitant gabapentin use.
A subgroup of 28 patients that had failed other anticon-
vulsants prior to topiramate was analyzed. RESULTS:
Patient characteristics: 14% Type 1 diabetes, 86% Type
2; mean age 64.9 years; 54% males; 93% Caucasian.
Most commonly affected areas: foot/toe (82%), calf
(36%), ﬁnger/hand (32%), thigh (21%). Most common
qualities: burning (57%), tingling (50%), aching (46%),
pins and needles (21%). Previous anticonvulsants
included gabapentin (82%), carbamazepine (29%), clon-
azepam (4%), and divalproex (4%). The most common
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reason for anticonvulsant discontinuation was lack of
efﬁcacy. Patients had PDN for 34 months on average
prior to starting topiramate. Mean duration of topira-
mate therapy was 17 months; mean total daily dose was
127mg. A total of 57% used topiramate monotherapy.
According to physician assessment, 46% (95% CI 28, 64)
were “very much improved” or “much improved” for
pain, 36% (95% CI 18, 54) for physical activity, and
39% (95% CI 21, 57) for sleep. None had worsening of
symptoms. A total of 32% experienced topiramate-
related adverse effects (AEs). In 67% no action was taken
for AEs. There were no discontinuations due to AEs or
lack of efﬁcacy. CONCLUSIONS: Topiramate was effec-
tive and well-tolerated for the treatment of PDN, even in
a group of difﬁcult to treat patients for whom other anti-
convulsants had failed.
PAIN—Cost Studies
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The management of back pain is controversial. Despite a
high incidence (between 15% and 40% in most Western
countries) and associated economic burden, considerable
uncertainty exists as to the effectiveness and cost-
effectiveness of alternative interventions for the condi-
tion. OBJECTIVES: To determine whether, from a UK
National Health Service (NHS) perspective, surgical sta-
bilisation of the spine is cost-effective when compared to
an intensive rehabilitation programme for the treatment
of patients with chronic low back pain. STUDY DESIGN:
Three hundred forty-nine patients (349) assessed as
having chronic low back pain were randomised to surgery
(176 patients) or rehabilitation (173 patients) at centres
across the UK. Patients were followed-up at 6, 12, and
24 months post randomisation. METHODS: Costs to the
NHS of initial treatment (surgery or rehabilitation), med-
ications, and all primary and secondary sector health care
contacts were collected for each patient out to 24 months.
Patient utility measured using the EuroQol EQ-5D ques-
tionnaire was combined with 24 month survival data to
calculate quality adjusted life years (QALYs). Results
were expressed using an incremental cost per QALY. Sta-
tistical techniques were used to examine stochastic uncer-
tainty surrounding cost, QALY, and cost per QALY
results. RESULTS: Preliminary analysis shows surgery to
be more costly than rehabilitation at 24 months follow-
ing randomisation. The main cost drivers appear to be
the initial surgical procedure and a higher proportion of
surgery patients receiving subsequent outpatient and
community care. No difference in QALYs was detected
between the two modes of treatment and the baseline
incremental cost per QALY exceeded £30,000. Examina-
tion of uncertainty surrounding key parameters did not
alter these results greatly. CONCLUSION: Preliminary
results from this trial, one of very few in orthopaedic
surgery in the UK, suggest that surgical stabilisation of
the spine for patients with chronic low back pain may be
more costly than alternative treatments with no clear
advantage in successful outcomes.
PAIN—Quality of Life
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OBJECTIVES: Epidemiological studies have consistently
shown that the prevalence of most pain conditions is
higher in women than in men. METHODS: Cross-
sectional survey in the county of Uppland, Sweden, 1995.
The questionnaire was completed by 5404 people
(response rate = 68%); this analysis of those aged 20–64
years included 4506 of the responders. RESULTS: Back
pain (22.7%) and shoulder pain (21.0%) were the most
commonly reported medical problems in the population,
while pain in arms/legs (15.7%) was ﬁfth and headache
(12.5%) was eighth in ranked order of prevalence. Major
gender differences were found. The prevalence of pain
conditions, especially headache, was higher among
women, who also reported more severe pain. Co-
morbidity between pain conditions and psychiatric and
somatic problems was higher among women. Health-
related quality of life (HRQoL; SF-36) also differed with
gender and type of pain. Headache affected the physical
dimensions of the HRQoL scale more in men than in
women, and affected the psychological dimensions more
in women than in men. Although pain conditions were
associated with poorer socioeconomic conditions and life-
style factors in both men and women, there were gender
differences. Education and unemployment were associ-
ated with pain only among men, while economic difﬁ-
culties, part-time work and being married were associated
with pain among women. Obesity, early disability retire-
ment, long term sick-leave and lack of exercise were asso-
ciated with pain conditions in both genders. Factors
associated with pain conditions were unevenly distributed
between genders. CONCLUSION: There are major dif-
ferences between men and women in the prevalence and
severity of self-reported pain in the population. Biologi-
cal factors may explain some of the differences but it is
suggested that the main explanation is the result of gender
disparities in work, economic situation, daily living,
